Bokemeyer C, Harstrick A, Schmoll H J, Köhne-Wömpner C H, Schöffski P, Poliwoda H
Department of Hematology/Oncology, University of Hannover Medical School, Germany.
Ann Oncol. 1992 Jun;3(6):487-8. doi: 10.1093/oxfordjournals.annonc.a058243.
Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29. Eight patients (30%) achieved partial responses, with a median duration of 8.5 months. The median time to progression was 5.5 months. Myelosuppression was the main toxicity. Only 74% of the planned dose intensity could be administered. This rapidly alternating treatment protocol is not superior to anthracycline single agent therapy.
28例未经预处理的转移性软组织肉瘤患者进入一项快速交替使用表柔比星/达卡巴嗪和异环磷酰胺的治疗方案：表柔比星100mg/m²，第1天；达卡巴嗪500mg/m²，第1天和第2天；异环磷酰胺6000mg/m²，24小时输注，第15天；第29天重复。8例患者（30%）获得部分缓解，中位缓解持续时间为8.5个月。中位疾病进展时间为5.5个月。骨髓抑制是主要毒性。仅能给予计划剂量强度的74%。这种快速交替治疗方案并不优于蒽环类单药治疗。
